Aaron Michels
Concepts (325)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Diabetes Mellitus, Type 1 | 66 | 2025 | 3618 | 7.300 |
Why?
| Autoantigens | 17 | 2025 | 416 | 3.480 |
Why?
| Receptors, Antigen, T-Cell | 15 | 2024 | 701 | 3.400 |
Why?
| Insulin | 28 | 2024 | 2318 | 3.100 |
Why?
| Islets of Langerhans | 16 | 2024 | 790 | 2.780 |
Why?
| Autoantibodies | 22 | 2025 | 1463 | 2.550 |
Why?
| Antineoplastic Agents, Immunological | 4 | 2022 | 173 | 2.000 |
Why?
| T-Lymphocytes | 12 | 2023 | 1922 | 1.970 |
Why?
| Programmed Cell Death 1 Receptor | 4 | 2019 | 226 | 1.720 |
Why?
| HLA Antigens | 4 | 2025 | 235 | 1.590 |
Why?
| Insulin-Secreting Cells | 9 | 2022 | 365 | 1.570 |
Why?
| CD4-Positive T-Lymphocytes | 15 | 2025 | 1046 | 1.560 |
Why?
| Hypoglycemic Agents | 9 | 2020 | 1214 | 1.460 |
Why?
| Autoimmunity | 14 | 2024 | 860 | 1.450 |
Why?
| Antibodies, Monoclonal | 5 | 2020 | 1355 | 1.340 |
Why?
| Autoimmune Diseases | 5 | 2019 | 423 | 1.190 |
Why?
| Insulin Antibodies | 4 | 2017 | 105 | 1.170 |
Why?
| Peptides | 6 | 2023 | 909 | 1.150 |
Why?
| Histocompatibility Antigens Class II | 7 | 2018 | 359 | 1.080 |
Why?
| HLA-DQ Antigens | 7 | 2019 | 179 | 1.040 |
Why?
| Immunologic Factors | 3 | 2019 | 229 | 1.010 |
Why?
| HLA-DR Antigens | 3 | 2022 | 225 | 0.960 |
Why?
| Antigen Presentation | 2 | 2018 | 204 | 0.890 |
Why?
| Protein Precursors | 3 | 2021 | 126 | 0.860 |
Why?
| Melanoma | 2 | 2022 | 749 | 0.860 |
Why?
| B7-H1 Antigen | 3 | 2021 | 185 | 0.820 |
Why?
| Models, Immunological | 2 | 2015 | 94 | 0.790 |
Why?
| Cell Cycle Checkpoints | 2 | 2020 | 95 | 0.790 |
Why?
| Peptide Fragments | 6 | 2016 | 685 | 0.780 |
Why?
| Immunotherapy | 7 | 2021 | 585 | 0.780 |
Why?
| Humans | 77 | 2025 | 128524 | 0.780 |
Why?
| Methyldopa | 2 | 2019 | 7 | 0.760 |
Why?
| Receptor-Like Protein Tyrosine Phosphatases, Class 8 | 5 | 2025 | 62 | 0.690 |
Why?
| HLA-DQ beta-Chains | 1 | 2020 | 61 | 0.680 |
Why?
| Polyendocrinopathies, Autoimmune | 2 | 2010 | 18 | 0.660 |
Why?
| Interferon-gamma | 2 | 2021 | 761 | 0.660 |
Why?
| Disease Susceptibility | 1 | 2021 | 334 | 0.660 |
Why?
| Health Fairs | 1 | 2019 | 9 | 0.660 |
Why?
| Stevens-Johnson Syndrome | 2 | 2019 | 38 | 0.640 |
Why?
| Antigens | 4 | 2018 | 352 | 0.640 |
Why?
| Preventive Medicine | 1 | 2018 | 41 | 0.590 |
Why?
| Child | 29 | 2025 | 20721 | 0.590 |
Why?
| Proinsulin | 2 | 2017 | 52 | 0.570 |
Why?
| Alleles | 5 | 2022 | 845 | 0.560 |
Why?
| Diabetic Ketoacidosis | 4 | 2025 | 198 | 0.560 |
Why?
| Epitopes | 5 | 2025 | 466 | 0.560 |
Why?
| Antibody Formation | 1 | 2018 | 287 | 0.530 |
Why?
| Adolescent | 26 | 2025 | 20213 | 0.530 |
Why?
| Influenza, Human | 1 | 2022 | 596 | 0.520 |
Why?
| Immunity, Cellular | 1 | 2018 | 267 | 0.510 |
Why?
| Dried Blood Spot Testing | 1 | 2016 | 91 | 0.510 |
Why?
| Genetic Predisposition to Disease | 8 | 2025 | 2266 | 0.510 |
Why?
| Rituximab | 1 | 2016 | 163 | 0.480 |
Why?
| Major Histocompatibility Complex | 2 | 2013 | 229 | 0.480 |
Why?
| Graft Rejection | 1 | 2018 | 557 | 0.470 |
Why?
| Hypoglycemia | 3 | 2016 | 426 | 0.460 |
Why?
| HLA-D Antigens | 1 | 2014 | 34 | 0.460 |
Why?
| Diet Therapy | 1 | 2014 | 34 | 0.460 |
Why?
| Lymphocyte Activation | 4 | 2020 | 1098 | 0.460 |
Why?
| Mice, Inbred NOD | 8 | 2024 | 582 | 0.460 |
Why?
| Protein Kinase Inhibitors | 1 | 2020 | 872 | 0.450 |
Why?
| Drug Hypersensitivity | 1 | 2015 | 81 | 0.450 |
Why?
| Addison Disease | 1 | 2014 | 43 | 0.440 |
Why?
| Adrenal Glands | 1 | 2014 | 71 | 0.440 |
Why?
| Antibodies | 1 | 2015 | 391 | 0.430 |
Why?
| Young Adult | 18 | 2025 | 12320 | 0.430 |
Why?
| Mass Screening | 3 | 2019 | 1152 | 0.420 |
Why?
| Hormone Replacement Therapy | 1 | 2014 | 91 | 0.420 |
Why?
| Biomarkers | 3 | 2021 | 3881 | 0.420 |
Why?
| Disease Progression | 6 | 2021 | 2603 | 0.410 |
Why?
| Child, Preschool | 15 | 2025 | 10373 | 0.400 |
Why?
| Blood Glucose | 4 | 2024 | 2092 | 0.400 |
Why?
| Prediabetic State | 1 | 2015 | 245 | 0.390 |
Why?
| Female | 37 | 2025 | 68127 | 0.390 |
Why?
| Male | 34 | 2025 | 62883 | 0.390 |
Why?
| Organophosphorus Compounds | 1 | 2011 | 77 | 0.360 |
Why?
| Infant | 10 | 2025 | 8913 | 0.360 |
Why?
| Glycine | 1 | 2011 | 163 | 0.350 |
Why?
| Animals | 22 | 2024 | 34501 | 0.350 |
Why?
| Carcinoma, Papillary, Follicular | 1 | 2010 | 8 | 0.340 |
Why?
| Struma Ovarii | 1 | 2010 | 7 | 0.340 |
Why?
| Immunosuppressive Agents | 1 | 2014 | 686 | 0.340 |
Why?
| Macromolecular Substances | 1 | 2010 | 211 | 0.340 |
Why?
| Endocrine System Diseases | 1 | 2010 | 32 | 0.330 |
Why?
| Receptors, Antigen, T-Cell, alpha-beta | 2 | 2022 | 334 | 0.320 |
Why?
| Adult | 28 | 2025 | 35315 | 0.320 |
Why?
| C-Peptide | 5 | 2016 | 163 | 0.310 |
Why?
| Transcription Factor 7-Like 2 Protein | 2 | 2018 | 22 | 0.300 |
Why?
| Haplotypes | 3 | 2020 | 471 | 0.290 |
Why?
| Carbamazepine | 2 | 2019 | 18 | 0.290 |
Why?
| Inflammation | 2 | 2017 | 2664 | 0.290 |
Why?
| Neoplasms | 2 | 2020 | 2465 | 0.280 |
Why?
| Pediatrics | 1 | 2015 | 1061 | 0.280 |
Why?
| Glutamate Decarboxylase | 4 | 2017 | 168 | 0.280 |
Why?
| Diabetes Mellitus, Type 2 | 2 | 2020 | 2430 | 0.270 |
Why?
| CD8-Positive T-Lymphocytes | 3 | 2021 | 840 | 0.270 |
Why?
| Middle Aged | 20 | 2022 | 30893 | 0.270 |
Why?
| Antilymphocyte Serum | 2 | 2016 | 63 | 0.250 |
Why?
| Granulocyte Colony-Stimulating Factor | 2 | 2016 | 71 | 0.250 |
Why?
| History, 21st Century | 2 | 2018 | 180 | 0.240 |
Why?
| Blood Glucose Self-Monitoring | 2 | 2024 | 599 | 0.240 |
Why?
| History, 20th Century | 2 | 2018 | 291 | 0.230 |
Why?
| Ovarian Neoplasms | 1 | 2010 | 489 | 0.230 |
Why?
| Pluripotent Stem Cells | 2 | 2022 | 77 | 0.230 |
Why?
| Mice | 12 | 2024 | 16579 | 0.230 |
Why?
| Receptors, Antigen, B-Cell | 1 | 2024 | 126 | 0.220 |
Why?
| Hybridomas | 3 | 2020 | 234 | 0.210 |
Why?
| Age of Onset | 1 | 2025 | 493 | 0.210 |
Why?
| Lipodystrophy, Congenital Generalized | 1 | 2023 | 1 | 0.210 |
Why?
| Protein Binding | 3 | 2021 | 2097 | 0.210 |
Why?
| Lipodystrophy | 1 | 2023 | 13 | 0.210 |
Why?
| CD3 Complex | 2 | 2020 | 101 | 0.200 |
Why?
| Enzyme-Linked Immunosorbent Assay | 2 | 2016 | 814 | 0.190 |
Why?
| T-Lymphocytes, Regulatory | 2 | 2022 | 374 | 0.180 |
Why?
| Histocompatibility Antigens | 1 | 2021 | 107 | 0.180 |
Why?
| Insulin, Regular, Human | 1 | 2020 | 42 | 0.180 |
Why?
| Molecular Sequence Data | 3 | 2015 | 2818 | 0.180 |
Why?
| Rhizotomy | 1 | 2000 | 4 | 0.180 |
Why?
| Polyethylene Glycols | 2 | 2016 | 597 | 0.180 |
Why?
| Virus Diseases | 2 | 2015 | 204 | 0.170 |
Why?
| Clinical Trials as Topic | 2 | 2018 | 998 | 0.170 |
Why?
| Polymorphism, Single Nucleotide | 2 | 2018 | 2065 | 0.170 |
Why?
| Brachial Plexus | 1 | 2000 | 28 | 0.170 |
Why?
| Retroviridae | 1 | 2020 | 97 | 0.170 |
Why?
| Glucagon-Like Peptides | 1 | 2020 | 51 | 0.170 |
Why?
| Histocompatibility Antigens Class I | 1 | 2021 | 195 | 0.170 |
Why?
| Case-Control Studies | 3 | 2022 | 3326 | 0.170 |
Why?
| Receptor-CD3 Complex, Antigen, T-Cell | 1 | 2019 | 9 | 0.170 |
Why?
| Muscle Spasticity | 1 | 2000 | 55 | 0.170 |
Why?
| Diagnostic Techniques, Endocrine | 1 | 2019 | 14 | 0.160 |
Why?
| Immunoassay | 1 | 2020 | 103 | 0.160 |
Why?
| Arm | 1 | 2000 | 109 | 0.160 |
Why?
| Stem Cells | 2 | 2021 | 578 | 0.160 |
Why?
| Blood Specimen Collection | 1 | 2019 | 33 | 0.160 |
Why?
| High-Throughput Nucleotide Sequencing | 1 | 2022 | 485 | 0.160 |
Why?
| Genotype | 2 | 2015 | 1831 | 0.160 |
Why?
| T-Lymphocytes, Cytotoxic | 1 | 2019 | 168 | 0.150 |
Why?
| HLA-DRB1 Chains | 1 | 2019 | 108 | 0.150 |
Why?
| Prognosis | 2 | 2018 | 3780 | 0.150 |
Why?
| Models, Molecular | 2 | 2015 | 1481 | 0.150 |
Why?
| Cell Line, Transformed | 1 | 2018 | 140 | 0.150 |
Why?
| Antibodies, Monoclonal, Humanized | 2 | 2014 | 759 | 0.150 |
Why?
| Transglutaminases | 2 | 2016 | 153 | 0.150 |
Why?
| High-Throughput Screening Assays | 1 | 2019 | 136 | 0.150 |
Why?
| Tissue Donors | 2 | 2021 | 386 | 0.140 |
Why?
| Community Health Services | 1 | 2019 | 225 | 0.140 |
Why?
| Treatment Outcome | 5 | 2019 | 10163 | 0.140 |
Why?
| Genetic Heterogeneity | 1 | 2017 | 57 | 0.140 |
Why?
| Treatment Failure | 1 | 2018 | 342 | 0.140 |
Why?
| Antibodies, Viral | 1 | 2021 | 593 | 0.140 |
Why?
| Controlled Clinical Trials as Topic | 1 | 2016 | 27 | 0.130 |
Why?
| Amino Acid Sequence | 3 | 2017 | 2041 | 0.130 |
Why?
| Radioimmunoassay | 1 | 2016 | 169 | 0.130 |
Why?
| Genetic Variation | 1 | 2021 | 934 | 0.130 |
Why?
| Luminescence | 1 | 2016 | 35 | 0.130 |
Why?
| Mutation | 3 | 2015 | 3692 | 0.130 |
Why?
| Mice, Transgenic | 2 | 2019 | 2069 | 0.130 |
Why?
| Administration, Oral | 1 | 2018 | 757 | 0.130 |
Why?
| Dideoxynucleosides | 1 | 2015 | 20 | 0.120 |
Why?
| Donor Selection | 1 | 2016 | 74 | 0.120 |
Why?
| Luminescent Measurements | 1 | 2016 | 78 | 0.120 |
Why?
| Immunologic Memory | 1 | 2017 | 339 | 0.120 |
Why?
| Antigen-Presenting Cells | 1 | 2015 | 150 | 0.120 |
Why?
| Monocytes | 2 | 2016 | 541 | 0.120 |
Why?
| Abatacept | 1 | 2014 | 47 | 0.120 |
Why?
| Sequence Homology, Amino Acid | 1 | 2015 | 368 | 0.110 |
Why?
| Vitamin B Complex | 1 | 2014 | 41 | 0.110 |
Why?
| Multifactorial Inheritance | 1 | 2015 | 149 | 0.110 |
Why?
| Niacinamide | 1 | 2014 | 73 | 0.110 |
Why?
| Early Medical Intervention | 1 | 2014 | 58 | 0.110 |
Why?
| Receptors, Antigen, T-Cell, gamma-delta | 1 | 2014 | 99 | 0.110 |
Why?
| Pharmacogenetics | 1 | 2015 | 171 | 0.110 |
Why?
| B-Lymphocytes | 1 | 2019 | 820 | 0.110 |
Why?
| Chromogranin A | 1 | 2013 | 42 | 0.110 |
Why?
| CD4 Antigens | 1 | 2013 | 137 | 0.110 |
Why?
| Dipeptidyl-Peptidase IV Inhibitors | 1 | 2013 | 45 | 0.110 |
Why?
| Secondary Prevention | 1 | 2014 | 220 | 0.100 |
Why?
| Immunoconjugates | 1 | 2014 | 101 | 0.100 |
Why?
| Interleukin-10 | 1 | 2015 | 299 | 0.100 |
Why?
| Colorado | 2 | 2021 | 4392 | 0.100 |
Why?
| Primary Prevention | 1 | 2014 | 185 | 0.100 |
Why?
| Diabetes Mellitus | 1 | 2021 | 1001 | 0.100 |
Why?
| alpha 1-Antitrypsin | 1 | 2014 | 103 | 0.100 |
Why?
| Myeloid Cells | 1 | 2014 | 142 | 0.100 |
Why?
| Multiprotein Complexes | 1 | 2014 | 147 | 0.100 |
Why?
| Amino Acid Motifs | 1 | 2013 | 209 | 0.100 |
Why?
| Incidence | 1 | 2019 | 2619 | 0.100 |
Why?
| Celiac Disease | 1 | 2016 | 287 | 0.100 |
Why?
| Pancreas, Artificial | 1 | 2013 | 70 | 0.100 |
Why?
| Aged | 5 | 2021 | 21971 | 0.100 |
Why?
| Kidney Transplantation | 1 | 2018 | 604 | 0.100 |
Why?
| Polymorphism, Genetic | 1 | 2015 | 639 | 0.100 |
Why?
| Sulfhydryl Compounds | 1 | 2014 | 185 | 0.100 |
Why?
| Alum Compounds | 1 | 2011 | 22 | 0.090 |
Why?
| Small Molecule Libraries | 1 | 2011 | 86 | 0.090 |
Why?
| Skin Neoplasms | 1 | 2018 | 832 | 0.090 |
Why?
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2014 | 343 | 0.090 |
Why?
| Cytokines | 2 | 2017 | 1985 | 0.090 |
Why?
| Structure-Activity Relationship | 1 | 2011 | 530 | 0.090 |
Why?
| Dendritic Cells | 1 | 2014 | 477 | 0.090 |
Why?
| Whole Body Imaging | 1 | 2010 | 20 | 0.090 |
Why?
| Dietary Proteins | 1 | 2011 | 128 | 0.090 |
Why?
| Thyroglobulin | 1 | 2010 | 26 | 0.090 |
Why?
| Radionuclide Imaging | 1 | 2010 | 123 | 0.080 |
Why?
| Diagnosis, Differential | 1 | 2014 | 1416 | 0.080 |
Why?
| Iatrogenic Disease | 1 | 2010 | 55 | 0.080 |
Why?
| Iodine Radioisotopes | 1 | 2010 | 142 | 0.080 |
Why?
| Thyroidectomy | 1 | 2010 | 88 | 0.080 |
Why?
| Self Tolerance | 1 | 2009 | 26 | 0.080 |
Why?
| Hysterectomy | 1 | 2010 | 119 | 0.080 |
Why?
| Organ Specificity | 1 | 2010 | 291 | 0.080 |
Why?
| Immune Tolerance | 1 | 2011 | 345 | 0.080 |
Why?
| Adrenal Insufficiency | 1 | 2009 | 31 | 0.080 |
Why?
| Mice, Inbred BALB C | 1 | 2011 | 1229 | 0.080 |
Why?
| Randomized Controlled Trials as Topic | 1 | 2014 | 1358 | 0.080 |
Why?
| Interferon-alpha | 1 | 2010 | 192 | 0.080 |
Why?
| Interleukin-2 | 1 | 2010 | 430 | 0.080 |
Why?
| Sensitivity and Specificity | 3 | 2019 | 1820 | 0.070 |
Why?
| Syndrome | 1 | 2009 | 335 | 0.070 |
Why?
| Vaccines | 1 | 2011 | 393 | 0.060 |
Why?
| Gene Expression Regulation | 1 | 2015 | 2506 | 0.060 |
Why?
| Mice, Inbred C57BL | 2 | 2017 | 5257 | 0.060 |
Why?
| Area Under Curve | 2 | 2016 | 281 | 0.060 |
Why?
| Histocompatibility Testing | 2 | 2017 | 120 | 0.060 |
Why?
| Leukocytes, Mononuclear | 2 | 2019 | 538 | 0.060 |
Why?
| Risk Assessment | 1 | 2014 | 3256 | 0.060 |
Why?
| Prospective Studies | 3 | 2023 | 7043 | 0.060 |
Why?
| Perilipin-1 | 1 | 2023 | 16 | 0.050 |
Why?
| Models, Biological | 1 | 2010 | 1693 | 0.050 |
Why?
| Cell Differentiation | 2 | 2022 | 1883 | 0.050 |
Why?
| Protein Tyrosine Phosphatase, Non-Receptor Type 2 | 1 | 2022 | 11 | 0.050 |
Why?
| Protein Processing, Post-Translational | 1 | 2025 | 450 | 0.050 |
Why?
| HLA-A2 Antigen | 1 | 2021 | 47 | 0.050 |
Why?
| Transcription Factors | 1 | 2009 | 1631 | 0.040 |
Why?
| Psychology, Child | 1 | 1981 | 36 | 0.040 |
Why?
| Seroepidemiologic Studies | 1 | 2021 | 156 | 0.040 |
Why?
| Neurologic Examination | 1 | 2000 | 114 | 0.040 |
Why?
| Spike Glycoprotein, Coronavirus | 1 | 2021 | 107 | 0.040 |
Why?
| NFATC Transcription Factors | 1 | 2020 | 78 | 0.040 |
Why?
| HLA-B15 Antigen | 1 | 2019 | 13 | 0.040 |
Why?
| Hand Strength | 1 | 2000 | 113 | 0.040 |
Why?
| Genes, Reporter | 1 | 2020 | 266 | 0.040 |
Why?
| Hand | 1 | 2000 | 152 | 0.040 |
Why?
| Flow Cytometry | 2 | 2014 | 1141 | 0.040 |
Why?
| Epitopes, T-Lymphocyte | 1 | 2020 | 185 | 0.040 |
Why?
| Adoptive Transfer | 1 | 2019 | 216 | 0.040 |
Why?
| Psychotic Disorders | 1 | 1981 | 153 | 0.040 |
Why?
| Adipose Tissue | 1 | 2023 | 591 | 0.040 |
Why?
| Genetic Vectors | 1 | 2020 | 311 | 0.040 |
Why?
| Phosphoproteins | 1 | 2021 | 330 | 0.040 |
Why?
| Antibody Specificity | 1 | 2018 | 182 | 0.040 |
Why?
| Cell- and Tissue-Based Therapy | 1 | 2018 | 74 | 0.040 |
Why?
| Gene Editing | 1 | 2018 | 68 | 0.040 |
Why?
| Cohort Studies | 2 | 2018 | 5369 | 0.040 |
Why?
| Immunization | 1 | 2020 | 411 | 0.040 |
Why?
| Molecular Dynamics Simulation | 1 | 2019 | 217 | 0.030 |
Why?
| Gene Frequency | 1 | 2018 | 504 | 0.030 |
Why?
| Stem Cell Transplantation | 1 | 2018 | 164 | 0.030 |
Why?
| Lymphocytes | 1 | 2019 | 366 | 0.030 |
Why?
| Receptors, CXCR3 | 1 | 2016 | 16 | 0.030 |
Why?
| CD56 Antigen | 1 | 2016 | 37 | 0.030 |
Why?
| HEK293 Cells | 1 | 2019 | 681 | 0.030 |
Why?
| Receptors, IgG | 1 | 2016 | 74 | 0.030 |
Why?
| Zinc Transporter 8 | 1 | 2016 | 86 | 0.030 |
Why?
| Forkhead Transcription Factors | 1 | 2016 | 179 | 0.030 |
Why?
| Graft Survival | 1 | 2018 | 503 | 0.030 |
Why?
| Cation Transport Proteins | 1 | 2016 | 129 | 0.030 |
Why?
| Skin | 1 | 2019 | 717 | 0.030 |
Why?
| Prevalence | 1 | 2021 | 2549 | 0.030 |
Why?
| T-Lymphocyte Subsets | 1 | 2016 | 410 | 0.030 |
Why?
| Single-Blind Method | 1 | 2014 | 269 | 0.030 |
Why?
| Chromatography, Ion Exchange | 1 | 2014 | 52 | 0.030 |
Why?
| Gastrins | 1 | 2013 | 9 | 0.030 |
Why?
| Colesevelam Hydrochloride | 1 | 2013 | 8 | 0.030 |
Why?
| Chromatography, Gel | 1 | 2014 | 127 | 0.030 |
Why?
| Overweight | 1 | 2018 | 525 | 0.030 |
Why?
| Allylamine | 1 | 2013 | 8 | 0.030 |
Why?
| Sodium-Glucose Transporter 1 | 1 | 2013 | 10 | 0.030 |
Why?
| Dimerization | 1 | 2014 | 188 | 0.030 |
Why?
| Bromocriptine | 1 | 2013 | 28 | 0.030 |
Why?
| Sodium-Glucose Transporter 2 | 1 | 2013 | 22 | 0.030 |
Why?
| Cells, Cultured | 1 | 2021 | 4008 | 0.030 |
Why?
| Drug Combinations | 1 | 2014 | 323 | 0.030 |
Why?
| Surface Plasmon Resonance | 1 | 2014 | 88 | 0.030 |
Why?
| Risk | 1 | 2016 | 852 | 0.030 |
Why?
| Sulfonylurea Compounds | 1 | 2013 | 47 | 0.030 |
Why?
| Risk Factors | 2 | 2018 | 9727 | 0.030 |
Why?
| Killer Cells, Natural | 1 | 2016 | 425 | 0.030 |
Why?
| Recombinant Proteins | 1 | 2016 | 1284 | 0.030 |
Why?
| Islet Amyloid Polypeptide | 1 | 2013 | 46 | 0.030 |
Why?
| Primary Cell Culture | 1 | 2013 | 159 | 0.030 |
Why?
| Proportional Hazards Models | 1 | 2016 | 1208 | 0.030 |
Why?
| Toll-Like Receptors | 1 | 2014 | 179 | 0.030 |
Why?
| Statistics, Nonparametric | 1 | 2014 | 423 | 0.030 |
Why?
| Thiazolidinediones | 1 | 2013 | 137 | 0.030 |
Why?
| Glucagon-Like Peptide 1 | 1 | 2013 | 113 | 0.020 |
Why?
| Leptin | 1 | 2013 | 218 | 0.020 |
Why?
| Interleukin-1beta | 1 | 2014 | 374 | 0.020 |
Why?
| Baculoviridae | 1 | 2011 | 44 | 0.020 |
Why?
| Reproducibility of Results | 1 | 2019 | 3023 | 0.020 |
Why?
| Down-Regulation | 1 | 2014 | 629 | 0.020 |
Why?
| Diabetic Angiopathies | 1 | 2013 | 263 | 0.020 |
Why?
| Severity of Illness Index | 1 | 2019 | 2736 | 0.020 |
Why?
| Electrophoresis, Polyacrylamide Gel | 1 | 2011 | 323 | 0.020 |
Why?
| Oxidation-Reduction | 1 | 2014 | 1001 | 0.020 |
Why?
| Thymus Gland | 1 | 2011 | 309 | 0.020 |
Why?
| Metformin | 1 | 2013 | 311 | 0.020 |
Why?
| Disease Models, Animal | 1 | 2019 | 3943 | 0.020 |
Why?
| Phenotype | 1 | 2017 | 3050 | 0.020 |
Why?
| Longitudinal Studies | 1 | 2016 | 2697 | 0.020 |
Why?
| Postoperative Complications | 1 | 2000 | 2479 | 0.020 |
Why?
| Gene Expression | 1 | 2013 | 1462 | 0.020 |
Why?
| Signal Transduction | 1 | 2020 | 4829 | 0.020 |
Why?
| Time Factors | 1 | 2016 | 6503 | 0.020 |
Why?
| Registries | 1 | 2013 | 1878 | 0.020 |
Why?
| Obesity | 1 | 2018 | 2860 | 0.020 |
Why?
| Cross-Sectional Studies | 1 | 2013 | 5040 | 0.010 |
Why?
| Aged, 80 and over | 1 | 2013 | 7040 | 0.010 |
Why?
| Cardiovascular Diseases | 1 | 2013 | 2018 | 0.010 |
Why?
| Language Development Disorders | 1 | 1981 | 42 | 0.010 |
Why?
| Mother-Child Relations | 1 | 1981 | 134 | 0.010 |
Why?
| Child Behavior Disorders | 1 | 1981 | 134 | 0.010 |
Why?
| Family | 1 | 1981 | 642 | 0.010 |
Why?
| United States | 1 | 2013 | 13876 | 0.010 |
Why?
| Communication | 1 | 1981 | 838 | 0.010 |
Why?
|
|
Michels's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|